Compass Therapeutics, Inc., was originally incorporated in Delaware on March 20, 2018 as Olivia Ventures, Inc. On June 17, 2020, the company changed its name to Compass Therapeutics, Inc. The Company is a clinical-stage biopharmaceutical company developing proprietary antibody therapies designed to harness the immune system for the treatment of solid tumors and hematological malignancies. The company's immuno-oncology product candidates include clinical-stage monoclonal antibodies and bispecific antibody combinations. These product candidates are designed to address three key components required for an effective immune response to cancer: inducing a strong innate immune response; activating the adaptive immune system; and mitigating immunosuppressive mechanisms by which tumors evade immune surveillance and activation.